Drug Profile
ONO 2231
Latest Information Update: 08 Feb 2010
Price :
$50
*
At a glance
- Originator Ono Pharmaceutical
- Class Neuroprotectants
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Stroke
Most Recent Events
- 15 May 2006 Phase-I clinical trials in Stroke in Europe (Injection)
- 18 May 2005 Phase-I clinical trials in Stroke in United Kingdom (Injection)